2Kino T,Hatanaka H,Hashimoto M,et al.FK506,a novel immunosuppressant isolated from a Streptomyces I Fermenation,isolation and physico-chemicaland biological characteristic[J].Antibit,1987,40(9):1249-1255.
3Taylor J,Alun J,Glenda A,et al.Sensitive specific quantitative analysis of tacrolimus(FK506)in blood by liquid chromatography-electrospray tandem mass spectrometry[J].Clin Chem,1996,42(2):279.
4Przepivrka D,Nash RA,Wingard JR,et al.Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor ma transplantation[J].Blood Marrow Transplant,1999,5(2):94.
5Mekki O,Lee C.Carrier setal theef fect of food on oral bioavail ability of tarcolimus (FK506)in liver transplant patients[J].Clin Pharmacol Ther,1993,53(2):229-230.
6Sewing K Fr.Pharmacokinetics,dosing principles and blood level monitoring of FK506[J].Transpl Proc,1994,26(6):3267-3269.
7Trimarchi HM,Truong LD,Brennan S,et al.FK506-associated thrombotic microangiopathy:report of two cases and review of the literature[J].Transplantion,1999,67(4):539.
8Yoshida EM,Buczkowski AK,Sirrs SM,et al.Post-transplant diabetic ketoacidosis-apossiple consequence of immunosupression with calcineurin inhibiting agents:a case series[J].Transpl Int,2000,13(1):69.
